Preclinical News and Research

RSS
AVEO third quarter total collaboration revenues increase to $6.2 million

AVEO third quarter total collaboration revenues increase to $6.2 million

4 Nov 2010
Antigenics awarded $424,720 grant under QTDP program

Antigenics awarded $424,720 grant under QTDP program

4 Nov 2010
Pfizer's two new compounds may be effective in treating alcohol, nicotine dependence

Pfizer's two new compounds may be effective in treating alcohol, nicotine dependence

4 Nov 2010
NormOxys' OXY111A candidate selected as ‘Top 10 to Watch’ at Windhover's meeting

NormOxys' OXY111A candidate selected as ‘Top 10 to Watch’ at Windhover's meeting

4 Nov 2010
Aestus receives $244,000 grant from QTDP program

Aestus receives $244,000 grant from QTDP program

4 Nov 2010
Millennium and Takeda initiate TAK-700 Phase III clinical trial in advanced prostate cancer

Millennium and Takeda initiate TAK-700 Phase III clinical trial in advanced prostate cancer

4 Nov 2010
Study identifies promising therapy to overcome limitation in brain's ability to recover function after stroke

Study identifies promising therapy to overcome limitation in brain's ability to recover function after stroke

4 Nov 2010
Bolder BioTechnology receives $1.2 million in Qualifying Therapeutic Discovery Project Grants

Bolder BioTechnology receives $1.2 million in Qualifying Therapeutic Discovery Project Grants

4 Nov 2010
Bristol-Myers Squibb and Simcere partner to co-develop oncology compound

Bristol-Myers Squibb and Simcere partner to co-develop oncology compound

4 Nov 2010
Synageva receives $2.3 million under QTDP program

Synageva receives $2.3 million under QTDP program

4 Nov 2010
Regulus receives $488,989 grant under QTDP program

Regulus receives $488,989 grant under QTDP program

4 Nov 2010
Alnylam third quarter revenue increases from $24.2 million to $27.7 million

Alnylam third quarter revenue increases from $24.2 million to $27.7 million

4 Nov 2010
GTx receives $1.2 million under QTDP program

GTx receives $1.2 million under QTDP program

3 Nov 2010
Safeguard Scientifics third quarter aggregate revenue of partner companies increases 73% to $109.6 million

Safeguard Scientifics third quarter aggregate revenue of partner companies increases 73% to $109.6 million

3 Nov 2010
EUREKA program confirms ability of HIFU technology to deliver cancer drugs

EUREKA program confirms ability of HIFU technology to deliver cancer drugs

3 Nov 2010
Amgen outlines key recommendations for implementing approval pathway for biosimilars

Amgen outlines key recommendations for implementing approval pathway for biosimilars

3 Nov 2010
BioCryst receives $1.1 million in grants under QTDP program

BioCryst receives $1.1 million in grants under QTDP program

3 Nov 2010
CONRAD receives $5 million award from USAID

CONRAD receives $5 million award from USAID

3 Nov 2010
Avila presents results of AVL-192 preclinical studies for HCV infection at AASLD Meeting

Avila presents results of AVL-192 preclinical studies for HCV infection at AASLD Meeting

3 Nov 2010
ImmunoGen to present clinical data of lead compounds at EORTC-NCI-AACR Symposium

ImmunoGen to present clinical data of lead compounds at EORTC-NCI-AACR Symposium

3 Nov 2010

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback